Dated market and regulatory developments that affect what GLP-1 treatment costs, newest first. 11 entries were added on October 15, 2026; earlier analysis pieces are below.
September 15 – October 15, 2026
· Medicare.gov · confirmed
Medicare Open Enrollment opens; Lilly sets its third-quarter results date
Medicare Open Enrollment runs October 15 to December 7, 2026, with changes taking effect January 1, 2027. Lilly said it will report third-quarter 2026 results on October 29.
What it means for cash-pay patients: If you are on Medicare, this is the window to check how your 2027 drug plan handles a GLP-1; read our open-enrollment checklist. Zepbound and Foundayo self-pay terms are worth re-checking after October 29.
· eden.health and providers' own pages · confirmed
Our October re-read: Eden drops its membership; Mochi, Henry Meds and MEDVi leave the index basket
We re-read the providers' own pages. Eden now lists compounded semaglutide at $99 and tirzepatide at $129 a month with no membership fee; Henry Meds, MEDVi and Oak Longevity no longer print a product price and Mochi Health does not print its membership amount; Shed, Found and Noom Med changed their ladders.
What it means for cash-pay patients: The compounded semaglutide index fell to 63.5 (July = 100) on a smaller, fully verified sample. See the price index.
CNBC: Walmart to cover Ozempic and Mounjaro for employees with type 2 diabetes in 2027
CNBC reported that Walmart will cover more than 250 prescriptions at no cost to employees in 2027, including Ozempic and Mounjaro for type 2 diabetes after a prior authorization, and still no GLP-1 coverage for weight loss. The details come from the news report, not a Walmart plan document.
What it means for cash-pay patients: Employees who want a GLP-1 for weight loss stay in the cash-pay market.
Ozari Health press release lists compounded GLP-1 plans from $86
A paid GlobeNewswire release from Ozari Health lists compounded semaglutide at $86 and tirzepatide at $125 a month on a quarterly-billed plan, not available in California. We have not read Ozari's own pricing pages, so it is not in the index.
What it means for cash-pay patients: Treat press-release prices as claims until the provider's own checkout page confirms them.
FDA posts warning letters to two websites selling unapproved semaglutide
FDA posted warning letters 737806 (dated September 23) and 737810 (dated September 24) to websites selling unapproved injectable semaglutide under the names "Semanat" and "Semanext".
What it means for cash-pay patients: A very low "generic semaglutide" price from an online seller is a reason for caution, not a bargain.
FDA's consumer page, current as of October 1, 2026, lists telehealth red flags, a 28-day discard rule for compounded multi-dose GLP-1 vials, a warning about semaglutide salt forms, and says retatrutide and cagrilintide cannot be used in compounding under federal law.
What it means for cash-pay patients: A vial that must be discarded after 28 days can change what a "month" of medication really costs.
· Tufts Health RITogether provider notice · confirmed
Rhode Island Medicaid stops covering GLP-1s prescribed only for weight loss
Under the state's FY2027 budget, Rhode Island Medicaid ended coverage of Foundayo, Saxenda, Wegovy and Zepbound when prescribed solely for weight loss, effective October 1, 2026. Coverage continues for type 2 diabetes and other approved uses.
What it means for cash-pay patients: Affected members move to self-pay or stop treatment. See GLP-1 in Rhode Island.
CMS FAQ on "the BALANCE Model not launching in Medicare in 2027"; Bridge runs through 2027
CMS's BALANCE Model page (modified September 29, 2026) answers a question about "the BALANCE Model not launching in Medicare in 2027" and says the Medicare GLP-1 Bridge will be extended through December 31, 2027.
What it means for cash-pay patients: Eligible Medicare enrollees can keep using the $50 Bridge for Foundayo, Wegovy or the Zepbound KwikPen through 2027.
FDA announced that federal prosecutors in Florida charged two Indian nationals with conspiracy and smuggling over counterfeit Ozempic distributed between July 2023 and April 2024. An indictment is an allegation.
What it means for cash-pay patients: Buy brand GLP-1s from licensed pharmacies or the manufacturers' own programs.
FDA's letter, dated September 18 and posted September 22, says Empower's compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products" and cites insanitary conditions.
What it means for cash-pay patients: Programs that fill through Empower may change pharmacies, formulas or prices. Ask which pharmacy fills your prescription.
FDA's April 30, 2026 proposal not to place semaglutide, tirzepatide or liraglutide on the 503B bulks list (91 FR 23431) had no final decision as of October 15, 2026.
Lilly still plans to file retatrutide with FDA in the first quarter of 2027; no FDA decision on CagriSema had been published.
No FDA recall of a compounded GLP-1 was posted between September 1 and October 7, 2026 in the openFDA enforcement data.